Litfulo access guide: country options for cross-border named-patient access

Editorial and clinical review: Reserve Meds clinical and regulatory team. Last reviewed 2026-06-04.

About Litfulo

Litfulo (ritlecitinib) is a Janus kinase 3 and TEC kinase family (JAK3 / TEC) inhibitor approved by the US Food and Drug Administration for severe alopecia areata in adults and adolescents 12 years and older. The current FDA label is available at accessdata.fda.gov. Litfulo is marketed by Pfizer. Reserve Meds coordinates US-sourced cross-border access to Litfulo under the named-patient and personal-import framework that governs reference-authority-approved medicines in the patient jurisdiction, with chain-of-custody documentation under the US Drug Supply Chain Security Act (DSCSA). The country-specific access guides listed below set out the regulatory pathway, the tertiary referral context, the documentation bundle the treating physician of record submits to the regulator, and the indicative drug-only cash-pay band for Litfulo in each jurisdiction Reserve Meds has authored.

Litfulo country-specific access guides

Reserve Meds has published 4 country-specific access guides for Litfulo. Each guide covers the regulatory pathway, the tertiary referral context, the documentation package, the indicative drug-only band, and the operational sequence Reserve Meds coordinates for that jurisdiction.

Other countries not yet authored

Reserve Meds has authored country-specific access guides for Litfulo in the 4 jurisdictions listed above. If your case sits in a country that is not yet on this list, that does not mean a pathway is unavailable. It means we have not yet published the country-specific guide for Litfulo. The Reserve Meds case team will scope your case under the same named-patient or personal-import framework that governs the published guides.

Request a Litfulo access scope for your country

Related Reserve Meds resources


Composite case examples; no individual patient is depicted. This content is for general information and does not constitute medical advice. Reserve Meds is a US-based concierge coordinator; we are not the prescriber and not the dispensing pharmacy. Clinical decisions remain with your treating physician.

Editorial review: Reserve Meds clinical and regulatory team. Last reviewed 2026-06-04.

Frequently asked questions

How can I get Litfulo if it is not approved or available in my country?

Reserve Meds coordinates US-sourced Litfulo for patients through a physician-led, named-patient cross-border pathway. Your treating physician provides the prescription and clinical justification; Reserve Meds prepares the named-patient documentation for your country and arranges DSCSA-compliant US sourcing and delivery to your physician or hospital pharmacy.

Can I access Litfulo through named-patient or compassionate-use import?

Yes. Named-patient access (also called compassionate use or personal import) is the core route Reserve Meds operates for Litfulo. Eligibility and paperwork depend on the regulator in your country, and Reserve Meds maps the specific pathway for each market it coordinates.

Do I need a prescription to access Litfulo through Reserve Meds?

Yes. Reserve Meds is not a pharmacy and does not prescribe. A valid prescription and clinical justification from your treating physician are required, and all clinical decisions remain with your physician.

How does Reserve Meds deliver Litfulo to a patient?

Reserve Meds sources Litfulo from a DSCSA-compliant US specialty supplier with full traceability and coordinates delivery to your treating physician or hospital pharmacy, with appropriate handling for the product.

How long does it take, and what does Litfulo cost through Reserve Meds?

After a short intake, the clinical team responds within one business day with case-specific feasibility, an indicative timeline, and a formal written quote. Cost depends on the destination, the prescribed regimen, and the duration of therapy, and is confirmed in writing before anything proceeds.

How do I start a request for Litfulo?

Submit a 60-second intake through the Reserve Meds patient portal, or message the concierge team on WhatsApp. A named coordinator follows up within 24 hours.